alopecia

Posts

Global Alopecia Drugs Market Insights Forecast to 2025

Global Alopecia Drugs Market Insights Forecast to 2025

/in /by

Global Alopecia Drugs Market Insights Forecast to 2025

This report studies the global market size of Alopecia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America, and the Middle East & Africa focuses on the consumption of Alopecia Drugs in these regions.

This research report categorizes the global Alopecia Drugs market by players/brands, region, type, and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.

Alopecia drugs are being used for unapproved clinical indication or extension to a milder form of approved indication or extension to related conditions. For instance, alopecia market heavily uses spironolactone and cyclosporine, which are primarily approved for other indications.

The global topical drugs market segment accounted for the maximum market share during 2017 and will continue to dominate the market until the end of 2025. Topical drugs are widely used in comparison to oral formulations. The increasing availability and popularity of new drugs, such as the AVODART drug, will fuel the growth prospects for the market during the forecast period.

In 2017, the global Alopecia Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Alopecia Drugs market based on company, product type, application and key regions.

The various contributors involved in the value chain of Alopecia Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Alopecia Drugs include

GlaxoSmithKline
Johnson & Johnson
Merck
Aclaris Therapeutics
Polichem
Promius Pharma
Ranbaxy Laboratories
Reckitt Benckiser
Regience
Samumed
RepliCel
Skinvisible Pharmaceuticals
Teva Pharmaceutical
Market Size Split by Type
Oral Alopecia Drugs
Topical Alopecia Drugs
Injectable Alopecia Drugs
Market Size Split by Application
Hospitals
Specialty Clinics
Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:

To study and analyze the global Alopecia Drugs market size (value & volume) by the company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Alopecia Drugs market by identifying its various sub-segments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Alopecia Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in the next few years.

To analyze the Alopecia Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Alopecia Drugs submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Alopecia Drugs are as follows:

History Year: 2013-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Alopecia Drugs Market Insights Forecast to 2025

Source

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

/in /by

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that was approved by the US Food and Drug Administration in March 2017 for the treatment of adult patients with moderate to severe atopic dermatitis not adequately controlled with topical therapies.

In addition to effectively treating a resistant case of atopic dermatitis, the eczema drug dupilumab (Dupixent, Regeneron Pharmaceutics) triggered hair growth in a young patient with longstanding alopecia totalis, investigators report.

The dual efficacy of the interleukin (IL)-4 receptor alpha antagonist, which was approved by the US Food and Drug Administration in March 2017 for the treatment of moderate to severe atopic dermatitis, may be explained by the immune characteristics shared by both conditions, Lauren R. Penzi, MD, from the Department of Dermatology, Massachusetts General Hospital, Boston, and colleagues write in a case report published online October 10 in JAMA Dermatology.

Atopic dermatitis is a TH2-mediated disease with elevated IL-4, IL-5, IL-13, and IL-31, and although the pathogenesis of alopecia totalis — an advanced form of alopecia areata — is not fully understood, recent studies point to a strong TH2 link as well, the authors write. Dupilumab improves eczema symptoms by blocking the signaling of IL-4 and IL-13 cytokines, which play a role in maintaining the immune response of TH2 cells.

The case report describes the treatment of a 13-year-old girl with a history of treatment-resistant atopic dermatitis since age 7 months and atopic totalis since age 2 years. Previous treatment for alopecia totalis with topical squaric acid and anthralin was not effective. Trial treatment for both conditions with pulsed prednisone and methotrexate led to some improvement in the dermatitis, but not the alopecia, and thus was discontinued, and topical steroid treatment for the dermatitis did not produce an adequate response.

The patient began weekly injections of dupilumab in 2017. After 6 weeks of treatment her eczema improved significantly and vellus hairs began growing on her scalp. “Nine months after beginning dupilumab treatment, the patient had grown pigmented, terminal hairs on approximately 60% of the scalp,” the authors write.

During an unplanned 2-month treatment hiatus related to insurance coverage, the patient reported hair shedding, which resolved when treatment was restarted. “At last follow-up, 11 months after the first dupilumab dose, considerable hair growth was noted,” the authors write.

The patient reported minimal dry eye, a side effect that has been reported previously with dupilumab treatment, as have other adverse reactions including injection-site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, and other herpes simplex virus infection, the authors explain. “There have been no reports to our knowledge of hair growth in alopecia areata related to dupilumab,” they note.

“Right now, it’s hard to know whether dupilumab could induce hair growth in other alopecia patients, but I suspect it may be helpful in patients with extensive active eczema and active alopecia areata,” senior author Maryanne Makredes Senna, MD, from the Department of Dermatology, Massachusetts General Hospital, Boston, said in a hospital news release.

Another possible explanation for the observed improvement in the patient’s alopecia, according to Amy McMichael, MD, professor and chair, Department of Dermatology at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, “might be that the eczema was so severe on the scalp that there was another form of hair loss called telogen effluvium taking place in addition to the alopecia areata.”

Telogen effluvium is a nonscarring, shedding form of hair loss that often occurs when there is an inflammatory insult to the scalp, McMichael told Medscape Medical News. “Once the dupilumab was able to clear the eczema, this may have ended the telogen effluvium, leaving only the remaining alopecia areata, possibly accounting for why there is still partial hair regrowth.”
It is too early to tell whether dupilumab could trigger hair regrowth in other patients with alopecia totalis or individuals with other types of hair loss. “We first need to clarify what kind of hair loss we are really discussing, since there are many forms. The form discussed by the authors, alopecia areata, [is] an autoimmune form of hair loss that is seen more commonly in those younger than age 40, but can occur in anyone of any age,” McMichael explained.

“As noted, this form of hair loss is mediated by white blood cells that have certain markers identifying them as TH2 cells, and atopic dermatitis is known to be mediated by these same kinds of cells, though the mechanism of each is very complex and differ in many ways.” As both disorders are often seen in the same patients, “the idea that a single treatment might work for both is not completely out of the realm of possibility and has been observed with other biologic medications in the past,” she added.

Clinical trials testing the whether dupilumab might improve alopecia areata are warranted, McMichael stressed, noting also that additional preclinical studies “may offer even more insight to the mechanism of this eczema drug on alopecia areata.”

The investigators report that they have submitted a proposal for a clinical trial of dupilumab in patients with extensive active eczema and active alopecia areata.

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

Source

 

Global and Chinese Alopecia Industry 2018 Market Research

Global and Chinese Alopecia Industry 2018 Market Research

/in /by

Global and Chinese Alopecia Industry 2018 Market Research report

The ‘Global and Chinese Alopecia Industry, 2013-2023 Market Research Report’ is a professional and in-depth study on the current state of the global Alopecia industry with a focus on the Chinese market.

The report provides key statistics on the market status of the Alopecia manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of Alopecia industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2018-2023 market development trends of Alopecia industry.

Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Alopecia Industry before evaluating its feasibility.

Overall, the report provides an in-depth insight of 2013-2023 global and Chinese Alopecia industry covering all important parameters.

TOC of Global and Chinese Alopecia Industry, 2018 Market Research Report

Chapter One Introduction of Alopecia Industry

Chapter Two Manufacturing Technology of Alopecia

Chapter Three Analysis of Global Key Manufacturers

Chapter Four 2013-2018 Global and Chinese Market of Alopecia

Chapter Five Market Status of Alopecia Industry

Chapter Six 2018-2023 Market Forecast of Global and Chinese Alopecia Industry

Chapter Seven Analysis of Alopecia Industry Chain

Chapter Eight Global and Chinese Economic Impact on Alopecia Industry

Chapter Nine Market Dynamics of Alopecia Industry

Chapter Ten Proposals for New Project

Chapter Eleven Research Conclusions of Global and Chinese Alopecia Industry

Global and Chinese Alopecia Industry 2018 Market Research report

Source

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia Market Insights, Forecast to 2025

/in /by

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia (Hair Loss Treatment) market is anticipated to grow at a CAGR of XX% by 2023, according to a new report published by ResearchVector Inc.

The report segments the market and forecasts its size, by volume and value, on the basis of application, by-products, and by geography (North America, Europe, Asia-Pacific, MEA and South America).

The Global Market for Alopecia (Hair Loss Treatment) to 2023 offers detailed coverage of guanidine Alopecia (Hair Loss Treatment) industry and presents main market trends. The market research gives historical and forecast market size, demand, and production forecasts, end use demand details, price trends, and company shares of the leading Alopecia (Hair Loss Treatment) producers to provide exhaustive coverage of the guanidine carbonate.

This research report includes the following contents:

  • Alopecia (Hair Loss Treatment) Product details, including pictures and technical specifications
  • Alopecia (Hair Loss Treatment) manufacturers, distributors and channels
  • Major players present in the Alopecia (Hair Loss Treatment)
  • Information on competitor market shares, revenue, unit sales etc
  • Breakdown by applications for the Market
  • Value chain and distributor details in the market

Key vendors:

  • Shiseido
  • Rohto
  • Unilever
  • Taisho
  • Angfa
  • LOreal
  • Kaminomoto
  • Merck
  • Yanagiya Honten
  • Amorepacific
  • Procter & Gamble
  • Himalaya
  • Gerolymatos International
  • Merz Pharma
  • Leader Teck
  • Vasu Healthcare
  • VLCC
  • Ales Group
  • Shanxi Ante
  • Wansheng Pharmaceutical
  • Advanced Skin and Hair
  • Humanwell Healthcare
  • Topfond
  • Lifes2good
  • Bawang
  • YNK Pharmaceutical
  • Apollo
  • Jingxiutang
  • Rogaine
  • Marico

Key regions:

United States, Canada, Mexico, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Malaysia, Philippines, Thailand, Vietnam, Germany, France, UK, Italy, Spain, Russia, Brazil, Rest of Central & South America, GCC Countries, Turkey, Egypt, South Africa

Additionally, the market is segmented by the following sectors

  • Shampoos and Conditioners
  • Medicine Product

Not only this, but figures covering the end-user applications are also provided according to the following classification

  • Men
  • Women

In summary, the report serves to study and analyse the Alopecia (Hair Loss Treatment) size (value & volume) by the company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. This report includes the estimation of market size for value (million US$) and volume (K MT).

Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia (Hair Loss Treatment), to estimate the size of various other dependent submarkets in the overall market.

Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

Overall the report is an excellent source for managers, researches and top executives alike to analyse and get clarity on the market standings and business forecast. We provide the information after thorough research and analysis saving precious hours and budget for the companies. We have been serving major clients like Sony, BCG, PWC, Mck, Hewlett Packard, Technicolor Etc.

Number of Pages 148

Published Date12 September 2018

Single User Price $3900.0

Enterprise User Price$7800.0

Global Alopecia Market Insights, Forecast to 2025

Source

Breakthrough Therapy for Alopecia Areata

Breakthrough Therapy for Alopecia Areata

/in /by

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata

Phase II data accepted for late-breaker news session at 2018 EADV Congress

“Pfizer strives to continue moving the JAK science forward with development of multiple JAKis with unique selectivity profiles that are being evaluated in clinical trials. These inhibitors have the potential of meeting significant unmet needs in multiple inflammatory conditions”

Pfizer Inc today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body.

The Breakthrough Therapy designation for alopecia areata was supported by positive results from a Phase 2 study, which will be presented during the late-breaking news session at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris on September 15, 2018. Currently, there are no FDA-approved treatments for alopecia areata, which impacts millions of people worldwide and is often associated with profound psychological consequences.

“We are encouraged by this Breakthrough Therapy designation as it underscores the potential of our JAK3 inhibitor to address a critical unmet need,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We are continuing to work closely with the FDA on the development process with the goal of bringing this potential new treatment to patients living with alopecia areata as soon as possible.”

Breakthrough Therapy designation was initiated as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) signed in 2012. As defined by the FDA, a Breakthrough Therapy is a drug intended to be used alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug.

Pfizer is also working with the European Medicines Agency (EMA) on the clinical development program for PF-06651600.

About Alopecia Areata

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body.

People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. The mean age of onset is between 25 and 35, but it can also impact children and adolescents and is seen in both sexes and all ethnicities.

More than half of patients with alopecia areata experience a poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety.

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600

Source

Oral JAK3 Inhibitor Granted for Alopecia Areata

Oral JAK3 Inhibitor Granted for Alopecia Areata

/in /by

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata

Phase II data accepted for late-breaker news session at 2018 EADV Congress

Pfizer Inc today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body.1,2

The Breakthrough Therapy designation for alopecia areata was supported by positive results from a Phase 2 study, which will be presented during the late-breaking news session at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris on September 15, 2018.

Currently, there are no FDA-approved treatments for alopecia areata, which impacts millions of people worldwide and is often associated with profound psychological consequences.1,2

“We are encouraged by this Breakthrough Therapy designation as it underscores the potential of our JAK3 inhibitor to address a critical unmet need,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We are continuing to work closely with the FDA on the development process with the goal of bringing this potential new treatment to patients living with alopecia areata as soon as possible.”

Breakthrough Therapy designation was initiated as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) signed in 2012.

As defined by the FDA, a Breakthrough Therapy is a drug intended to be used alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug.3

Pfizer is also working with the European Medicines Agency (EMA) on the clinical development program for PF-06651600.

About Alopecia Areata

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches.1,2 The mean age of onset is between 25 and 35, but it can also impact children and adolescents and is seen in both sexes and all ethnicities.1,2 More than half of the patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety.1

About PF-06651600 and Pfizer’s Kinase Inhibitor Leadership

The JAK pathways are believed to play an important role in inflammatory processes as they are involved in signaling for over 50 cytokines and growth factors, many of which drive immune-mediated conditions.4 JAK inhibition offers the potential for new advanced treatment options for these conditions through unique and targeted selectivity.5

“Pfizer strives to continue moving the JAK science forward with development of multiple JAKis with unique selectivity profiles that are being evaluated in clinical trials. These inhibitors have the potential of meeting significant unmet needs in multiple inflammatory conditions,” said Michael Vincent, Chief Scientific Officer, Pfizer Inflammation & Immunology.

PF-06651600 is an oral small molecule that selectively inhibits Janus kinase (JAK) 3.5 PF-06651600 is also under investigation for the treatment of rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Pfizer has established a leading kinase research capability with multiple unique kinase inhibitor therapies in development. As a pioneer in JAK science, the Company is continuing to advance several investigational programs for molecules with novel selectivity profiles, which, if approved, could potentially deliver transformative therapies for patients. In addition to PF-06651600, Pfizer has the following kinase inhibitors in trials across multiple indications:

PF-04965842: A selective JAK1 inhibitor in Phase 3 clinical trials for the treatment of atopic dermatitis(AD)6; PF-04965842 received Breakthrough Therapy designation from the FDA for the treatment of patients with moderate-to-severe AD
PF-06700841: A tyrosine kinase 2(TYK2)/JAK1 inhibitor under investigation for the treatment of psoriasis, Crohn’s disease, ulcerative colitis and alopecia areata
PF-06650833: An interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor under investigation for the treatment of rheumatoid arthritis
PF-06826647: A TYK2 inhibitor under investigation for the treatment of psoriasis and inflammatory bowel disease (IBD)

Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of September 5, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Oral JAK3 Inhibitor Granted for Alopecia Areata

Source

Global Alopecia Drugs Market Insights Report

Alopecia Market Pipeline H1 Review

/in /by

Alopecia Market Pipeline H1 Review Products in Clinical Stage, Methodology, Therapeutic Landscape and R&D Progress

Alopecia Market – Pipeline Review H1 2018, provides detail overview of Alopecia development scenario.

This report delivers top-line data relating to the Alopecia Market pipeline landscape and also includes important players/vendors, Drugs Profile, Therapeutics Development, Molecule Type, Mechanism of Action.

Alopecia Market report additionally, provides an overview of key players involved in therapeutic development for Alopecia Market and features dormant and discontinued projects. The report also covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

Ask for PDF Sample of this Alopecia Market Report https://www.absolutereports.com/enquiry/request-sample/11716319

Some of The Key Players of Alopecia Market Pipeline Therapeutics Include: Aclaris Therapeutics Inc, Allergan Plc, Almirall SA, AndroScience Corp, Berg LLC, BiologicsMD Inc, BirchBioMed Inc, Brickell Biotech Inc, Bristol-Myers Squibb Co, Cassiopea SpA and More

Alopecia Market Report Highlights:

Alopecia Market Pipeline report guide covers comprehensive information on the therapeutics under development for Alopecia Market complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Alopecia Market pipeline helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.

The Scope of Alopecia Market:

Alopecia Market pipeline support provides a snapshot of the global therapeutic landscape.
The pipeline guide reviews key companies involved in Alopecia therapeutics and enlists all their major and minor projects.

Alopecia pipeline help to covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Alopecia Market pipeline adviser to evaluates therapeutics based on a mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The guide is built using data and information sourced from company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

Reasons to buy of Alopecia Market:

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with the potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Alopecia Market
Classify potential new clients or partners in the target demographic.

Price of Report: $ 2000 (Single User License)

Purchase Report at https://www.absolutereports.com/purchase/11716319

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alopecia Market pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from a pipeline.

Alopecia Market Pipeline H1 Review

Source

Global Androgenic Alopecia Drug Market 2018

Global Androgenic Alopecia Drug Market 2018

/in /by

Global Androgenic Alopecia Drug Market 2018 Analysis and Overview by QY Market Research

QY Market Research has recently published the latest report titled Global Androgenic Alopecia Drug Market Report 2018. Androgenic Alopecia Drug Market report gives complete global coverage of Androgenic Alopecia Drug market data from 2013 to 2018.

This Androgenic Alopecia Drug report starts with the review of Androgenic Alopecia Drug industry chain structure and defines the Androgenic Alopecia Drug business growth rate, trend, current status, investigates global Androgenic Alopecia Drug market share/volume and forecast up to 2023.

Worldwide Androgenic Alopecia Drug market report analyzes world’s main regions and additionally provides Androgenic Alopecia Drug industry top player’s Profiles/Analysis (Allergan,Inc., Histogen,Inc., R-TechUeno,Ltd., HygeiaTherapeutics,Inc., SWITCHBiotechLLC, PolichemS.A., KasiakResearchPvt.Ltd. ), regional coverage, product insights, Androgenic Alopecia Drug product types and product application insights.

Global Androgenic Alopecia Drug Market esteemed at XX million USD in last year(2017) and Androgenic Alopecia Drug market report expected it to reach XX million USD in forthcoming years during(2018-2023). The Worldwide Androgenic Alopecia Drug Market volume is predicted to boost a spectacular growth at XXX% of CAGR during the forecast duration.

The years considered to anticipate the market size of Androgenic Alopecia Drug are Base Year: 2017, Estimated Year: 2018, History Period/Year(last 5 years Historical data): 2013-2017, and Forecast Period/Year 2018 to 2023.

Top Manufacturers/Companies Included in Global Androgenic Alopecia Drug Market Report are: Allergan, Inc., Histogen, Inc., R-TechUeno, Ltd., HygeiaTherapeutics, Inc., SWITCHBiotechLLC, PolichemS.A., KasiakResearchPvt.Ltd.

Androgenic Alopecia Drug Industry Regional Analysis and Market Insights:

Regionally Androgenic Alopecia Drug market report isolated globally into some major key Regions, with revenue (million USD), Androgenic Alopecia Drug sales data (K Units), Androgenic Alopecia Drug market share (%) and growth rate of Androgenic Alopecia Drug industry for mentioned regions.

The Androgenic Alopecia Drug study report contains Androgenic Alopecia Drug market in North America(United States, Canada, Mexico), Androgenic Alopecia Drug business in Central & South America(Argentina, Chile, Brazil), Androgenic Alopecia Drug industry in Europe(UK, Spain, Germany, Italy, France, and Russia), Androgenic Alopecia Drug marketplace in the Middle East & Africa(Turkey, Egypt, Saudi Arabia, and South Africa) and Androgenic Alopecia Drug market in Asia-Pacific(India, China, Japan, South Korea, Indonesia, Singapore, Australia). The Androgenic Alopecia Drug Report additionally gives Key Partners with Androgenic Alopecia Drug producer, Androgenic Alopecia Drug Subcomponent Makers, Androgenic Alopecia Drug Traders/Wholesalers/Distributors, Downstream Vendors and Androgenic Alopecia Drug Industry Unions.

On the basis of Product Type, the Global Androgenic Alopecia Drug industry report shows the product price (USD/Unit), sales volume (K Units), Androgenic Alopecia Drug market share (%), production, Androgenic Alopecia Drug revenue (Million USD), and growth rate of each type, mainly split into; RK-023, Refagro, RCH-01, SM-04554, HYG-440, Others.

On the basis of Applications/end users, the Global Androgenic Alopecia Drug Market mainly focuses on the outlook and status for top Androgenic Alopecia Drug applications/end users, Androgenic Alopecia Drug market size, Share, consumption (sales), sales volume and growth rate for each application, including; Clinic, Hospital, HomeUse.

This Androgenic Alopecia Drug Market 2018 Study Report offers:

• A review of The Worldwide market for Global Androgenic Alopecia Drug Market and related advancements.
• In-depth analyses of Global market trends, with data from 2013, estimates for 2014 and 2017, and prediction of CAGR through 2023.
• A Clear Forecast prospect for geographical segments (regions) and also sub-segments will extend at the most exalted rate.
• Essential techniques for growth, and the demand for new applications and new products.
• Brand Procedure, Target Clients and Pricing Technique.
• Competitive landscaping of key market players.

List of Chapters (TOC) of Global Androgenic Alopecia Drug Market 2018 Study Report Contains the Following Points:

Chapters 1. Androgenic Alopecia Drug Industry Overview.
Chapters 2. Worldwide Androgenic Alopecia Drug Market Competition by Prime Players/Providers, Product Type, and Application.
Chapters 3. United States Androgenic Alopecia Drug Market Share and Androgenic Alopecia Drug Sales Volume by Key Players, Product Type & Application.
Chapters 4. Europe Androgenic Alopecia Drug Market Share, Growth Rate, & Sales.
Chapters 5. India Androgenic Alopecia Drug (Deals Cost, Value and Volume).
Chapters 6. China Androgenic Alopecia Drug Industry (Sales Price, Value and Volume).
Chapters 7. Japan Androgenic Alopecia Drug Marketplace Growth Rate, Sales Price Trend, Income.
Chapters 8. South-east Asia Androgenic Alopecia Drug Market (Sales Price, Value and Volume).
Chapters 9. Global Androgenic Alopecia Drug Providers/Players Profiles and Deals Information.
Chapters 10. Production Cost Analysis of Androgenic Alopecia Drug business.
Chapters 11. Androgenic Alopecia Drug Downstream Consumers, Sourcing Method, Industrial Chain.
Chapters 12. Worldwide Androgenic Alopecia Drug Traders/Distributors, Marketing Strategy Analysis.
Chapters 13. Androgenic Alopecia Drug Industry Impact Factors Analysis.
Chapters 14. Worldwide Androgenic Alopecia Drug Market Forecast (2018-2023).
Chapters 15. Worldwide Androgenic Alopecia Drug Market Research and Development Status, Research Findings and Conclusion.
Chapters 16. Appendix.

Ask Full Table of Content (TOC) with Graphs, Figures, Tables Here: http://www.qymarketresearch.com/

Global Androgenic Alopecia Drug Market 2018

Source

Global Alopecia Drugs Market Insights Report

Alopecia pipeline review

/in /by

Alopecia pipeline review H2 2018 just published

If you are want to study the Alopecia industry or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players.

If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body.

Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Key Players included in the research study are Aclaris Therapeutics Inc, Allergan Plc, Almirall SA, AndroScience Corp, Berg LLC, BiologicsMD Inc, BirchBioMed Inc, Brickell Biotech Inc, Bristol-Myers Squibb Co, Cassiopea SpA, Concert Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Dong-A Socio Holdings Co Ltd, Eli Lilly and Co, Energenesis Biomedical Co Ltd, Follica Inc, Histogen Inc, Japan Tobacco Inc, JW Pharmaceutical Corp, Kuhnil Pharmaceutical Co Ltd, Lee’s Pharmaceutical Holdings Ltd, Medivir AB, NovaLead Pharma Pvt Ltd, OliX Pharmaceuticals Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Quark Pharmaceuticals Inc, RXi Pharmaceuticals Corp, Samumed LLC, Taisho Pharmaceutical Holdings Co Ltd & Tigo GmbH.

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Alopecia pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision-making capabilities and helps to create effective marketing strategies to gain a competitive advantage in healthcare and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real-time basis.

Extracts of Chapters from Alopecia – Pipeline Review, H2 2018
Chapter 1, to describe the definition, overview and Therapeutics Development of Alopecia.
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes.
Chapter3, Therapeutics Assessment of Alopecia by Target, Mechanism of Action, Route of Administration and by Molecule Type.
Chapter4, to display company profile involved in Therapeutics Development.
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Alopecia.
Chapter 6,7, to describe Alopecia Appendix, Methodology, Coverage, Secondary Research, Primary Research, Expert Panel Validation and Contact Us.

Objective of this study

– To provides a snapshot of the global therapeutic landscape of Alopecia.
– To reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Alopecia therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Alopecia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews the latest news related to pipeline therapeutics for Alopecia

This research report helps to

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Alopecia.
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Alopecia pipeline review

Source

barber alopecia hair loss

Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss

/in /by

The Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss and Refer for Medical Treatment

SKIN: The Journal of Cutaneous Medicine® Article-Scarring Alopecia: The Attitudes, Knowledge, and Referral Patterns of Hair Stylists and Barbers

Training hairdressers in hair loss screening and patient education present a promising opportunity for early detection and treatment of potentially irreversible hair loss.”

Disorders of hair loss affect a large portion of the population. A group of hair loss disorders known as “scarring alopecia” or scarring hair loss presents a particular challenge to patients and physicians.

This type of alopecia, which affects up to 3% of people suffering from hair loss, is associated with inflammation that causes scar tissue to replace hair follicles. This often results in permanent hair loss.

Early diagnosis and treatment by an expert are extremely important in ensuring positive outcomes.

However, it is not uncommon for patients with scarring alopecia to have a delayed presentation to medical care, often because they are unaware of the differences between this entity and the more common male- and female-pattern hair loss.

Hairdressers and barbers encounter customers with hair loss on a near-daily basis and thus are uniquely positioned to help identify scarring alopecia early in the disease course.

Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss

In an article published in SKIN: The Journal of Cutaneous Medicine®, Julia Accetta, BS, and coauthors from the Department of Dermatology at the Tulane University School of Medicine investigated the knowledge and attitudes of hair stylists with regards to scarring alopecia.

Accetta and her team surveyed 118 stylists and found that the majority had been asked by clients to evaluate for hair loss, whereas about half reported routinely referring clients with hair loss to a dermatologist expert.

Further, the authors noted that although stylists’ knowledge of scarring hair loss varied, around 80% stated that they would be willing to undergo specific training to allow them to better identify specific hair loss disorders and to discuss this with their clients.

According to Accetta, “training hairdressers in hair loss screening and patient education presents a promising opportunity for early detection and treatment of potentially irreversible hair loss.”

SKIN: The Journal of Cutaneous Medicine® is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.

For more details please visit www.jofskin.org

Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss

Source

Alopecia Market Growth Opportunities